Showing results (401-410 of 661) with videos related to
Sort By:
Pageof 67
Oncotarget|May 15, 2013
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapyRabin Said, David S Hong, Carla L Warneke, et al.Physics in Medicine and Biology|December 20, 2018
A novel magnetic resonance elastography transducer concept based on a rotational eccentric mass: preliminary experiences with the gravitational transducerJurgen Henk Runge, Stefan Heinz Hoelzl, Jelizaveta Sudakova, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trialOmar Eton, Sewa S Legha, Agop Y Bedikian, et al.Cancer|February 24, 2012
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitorsWoo-Young Kim, Ludmila Prudkin, Lei Feng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2024
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell CarcinomasFaye M Johnson, Madison P O'Hara, Lacin Yapindi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2011
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosisXiming Tang, Humam Kadara, Carmen Behrens, et al.Molecular Cancer Research : MCR|December 1, 2016
High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIVHeather M Walline, Thomas E Carey, Christine M Goudsmit, et al.Journal of the National Cancer Institute|April 5, 2017
A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic CancerSeetharaman Balasenthil, Ying Huang, Suyu Liu, et al.Cancer Research|October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsFilip Janku, Jennifer J Wheler, Aung Naing, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancerGustavo Schvartsman, S Andrew Peng, Giorgios Bis, et al.Pageof 67